DISPOSABLE SYRINGE MARKETS
(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers
## TABLE OF CONTENTS

1. **Introduction**  
   1.1 Statement of Report  
   1.2 About this Report  
      1.2.1 Scope of the Report  
      1.2.2 Objectives  
      1.2.3 Methodology  
   1.3 Executive Summary  

2. **Syringe Types: An Overview**  
   2.1 Disposable Syringes  
   2.2 Safety Syringes  
      2.2.1 Available Safety Syringe Technologies  
      2.2.2 Retrofitted Syringes  
      2.2.3 Automatically Retractable Syringes  
      2.2.4 Manually Retractable Syringes  
      2.2.5 Insulin Syringes  
      2.2.6 Tuberculin Syringes  
      2.2.7 Prefilled Syringes  
         2.2.7.1 Components of a Prefilled Syringe  
         2.2.7.2 Benefits of Prefills  
         2.2.7.3 Prefills: The Future of Drug Delivery  
         2.2.7.4 Wider Applications of Prefilled Syringes  
         2.2.7.5 Making Improvements in Components of Prefilled Syringes  
         2.2.7.6 Biologic Drugs and Overfill  
         2.2.7.7 Benefits of Cyclic Olefin Polymers  
         2.2.7.8 Overcoming Variability in Glass Syringes  
         2.2.7.9 Impact of Silicone Oil on Delivery  
         2.2.7.10 Migrating Risk for Protein Aggregation  
         2.2.7.11 Key Advantages of Prefilled Syringes  
      2.2.8 Production of Standard Prefilled Syringes  
      2.2.9 Available Prefilled Syringes in the Market  
      2.2.9.1 Baxter BioPharma Solutions  
      2.2.9.2 BD Medical’s Prefilled Segment  
      2.2.9.3 Catalent Pharma Solutions  
      2.2.9.4 Cook Pharma’s Filling and Packaging  
      2.2.9.5 Gerresheimer AG’s Syringe Designs  
      2.2.9.6 Unilife Corporation’s New Approach  
      2.2.9.7 West Pharmaceutical Services, Inc.’s Prefilled Syringes  
   2.3 Pen Injectors  
      2.3.1 Insulin Pens  
      2.3.2 Buyer’s Guide for Reusable Insulin Pens  
      2.3.2.1 Technical Considerations for Insulin Pens  
      2.3.2.2 Technical Considerations for Insulin Cartridges  
      2.3.2.3 Technical Considerations for Pen Needles  
      2.3.2.4 Device Considerations  
      2.3.2.5 User Considerations  
      2.3.3 Market Review of Selected Insulin Pens  
      2.3.3.1 Autopen 24 and Autopen Classic from Owen Mumford  
      2.3.3.2 HumaPen Luxura and Luxura HD from Eli Lilly  
      2.3.3.3 HumaPen Memoir from Eli Lilly  
      2.3.3.4 NovoPen 3 and NovoPen Junior/Demi from Novo Nordisk  
      2.3.3.5 OptiClik from Sanofi-Aventis  
      2.3.3.6 OptiPen Pro from Sanofi-Aventis  

© 2013 TriMark Publications, LLC. All rights reserved.  
www.trimarkpublications.com
2.4 Advanced Injection Devices 38
2.4.1 Insulin Delivery Device Technology 38
2.4.2 Biologic Delivery Device Technology 39
2.4.3 Alternative Delivery Technologies 40
2.5 Needle-Free Injectors 40
2.5.1 Needleless Injector from Injex 41
2.5.2 Jet Syringes from Injex 41
2.5.3 Syrijet 42
2.5.4 PenJet 42
2.5.5 Needle-Free Injector for Human Growth Hormones 42

3. Award Winning Syringes 44
3.1 Episure AutoDetect Syringe 44
3.2 ConfiDose 44
3.3 Humatrope Reconstitution Devices 45
3.4 Vascez Plungerless Syringe 45
3.5 Powr Syringe Injector 45
3.6 NovoFine Autocover Automatic Safety Pen Needle 46
3.7 Rev Vac Auto-Retractable Vacuum Safety Syringe 46

4. Syringe Industry: Overview 47
4.1 Common Diseases Transmitted by Unsafe Needle Use and Needlesticks 47
4.2 Most Common Instances of Needlestick Injuries 48
4.3 Needle Phobia and Patients' Anxieties 48
4.4 Global Transition to Safety Medical Devices 48
4.5 U.S. Regulation 49
4.6 Worldwide Regulation 50
4.7 Enforcing Compliance with Sharps Safety Legislation 50
4.8 Example of an OSHA Violation 50
4.9 Target Market Awaiting Premium Products 50
4.10 Current Types of Safety Syringes 51
4.10.1 Safety Syringes with a Needlestick Protection Device 52
4.10.2 Needle Guard 52
4.10.3 Needle Sheath 53
4.10.4 Retractable Syringes 53
4.10.4.1 Spring-Based, Non-Controlled, Retracting Needle Syringe 53
4.11 Need for Safety Syringe Products 54
4.12 Limitations of Existing Clinical Syringes 55
4.13 Limitations of Existing Prefilled Syringes 55
4.14 Market Expansion for Safety Syringes 55
4.15 Technological Advancements in Disposable Syringes 55
4.16 Reconstitution inside Sterile Syringes 56
4.16.1 Vetter Lyo-Ject 56
4.17 Plungerless Prefilled Syringes 56
4.18 The Disposable UniJect 56
4.19 Needle-Free Injection 57

5. Disposable Syringes: Market Analysis 58
5.1 Volume of Syringes Used in Healthcare 58
5.2 Syringe Sizes Required for Injectable Drugs 59
5.3 Domination of Syringes in Parenteral Drug Delivery Market 59
5.4 Global Market for Disposable Syringes 60
5.4.1 Global Market for Disposable Syringes by Product Segmentation 61
5.4.2 Global Market for Safety Syringes by Segmentation 61
5.4.3 Combined Market for Injection Devices 62
5.5 U.S. Market for Hypodermic Safety Syringes 63
5.5.1 Disposable Syringes: U.S. Market Segments 63
5.5.2 Types of Safety Syringes Used in U.S. Hospitals 64
5.5.3 U.S. Adoption of Safety Syringes 65
5.5.4 Competitive Landscape in the U.S. 66
5.5.5 Price of Safety Syringes in the U.S. 66
5.5.6 U.S. Disposable Syringe Market 67
5.5.7 U.S. Safety Hypodermic Syringe Market 67
5.6 European Market for Disposable Syringes 68
5.6.1 European Market for Safety Syringes 69
5.7 Prefill Market Trends 69
5.7.1 The Shift from Vials to Prefilled Syringes 70
5.7.2 Prefilled Syringes: Market Dynamics 70
5.7.3 Importance of Prefilled Syringes to Extend Brand Life 71
5.7.4 Biggest Markets for Prefilled Syringes 71
5.7.5 Dealing with the Latest Trends in Prefilled Syringe Market 72
5.7.6 Market Opportunities for Prefilled Syringes 72
5.7.7 Pharmaceutical Share of Key Prefilled Therapeutic Market 73
5.7.8 Specialty Pipeline Drugs Targeted for Use with Prefilled Syringes 74
5.7.9 Therapeutic Usage of Prefilled Syringes 75
5.7.9.1 Anti-Infectives in Prefilled Syringes 75
5.7.9.2 Cardiovascular Drugs in Prefilled Syringes 76
5.7.9.3 Central Nervous System Drugs in Prefilled Syringes 76
5.7.9.4 Hematology Drugs in Prefilled Syringes 76
5.7.9.5 Human Growth Hormones in Prefilled Syringes 76
5.7.9.6 Musculoskeletal Drugs in Prefilled Syringes 77
5.7.9.7 Obstetrics Drugs in Prefilled Syringes 77
5.7.9.8 Oncology Drugs in Prefilled Syringes 77
5.7.9.9 Vaccines in Prefilled Syringes 77
5.7.10 Flexible Administration Requirements of Prefilled Syringes 77
5.7.11 Biotech Blockbusters Available in Prefilled Syringes 78
5.7.12 Selected Drugs Available in Prefilled Syringes 79
5.7.12.1 Ovidrel Prefilled Syringe 79
5.7.12.2 Enbrel Prefilled Syringe 79
5.7.12.3 Biocon’s Prefilled Safety Syringes 79
5.7.12.4 Pegasys 80
5.7.12.5 Afluria 80
5.7.12.6 Enzira 81
5.7.12.7 Fluzone Vaccine 81
5.7.12.8 NovoLog® Insulin Prefilled Syringe 82
5.7.12.9 NovoLog® Insulin Prefilled Syringe 82
5.7.12.10 GlaxoSmithKline’s Vaccines in Prefilled Syringes 82
5.7.13 Selected Providers of Syringe Prefilling Services and Products 82
5.7.13.1 Althea Technologies, Inc. 82
5.7.13.2 Althea’s Clinical Manufacturing 83
5.7.13.3 Althea’s Fill/Finish Services 83
5.7.13.4 Althea’s Contract Manufacturing 83
5.7.14 Baxter International, Inc. 84
5.7.14.1 Baxter’s Contract Manufacturing 85
5.7.14.2 Baxter’s Fill/Finish Services 85
5.7.14.3 Baxter’s Prefilled Syringes Capability 85
5.7.14.4 Baxter’s Vials 86
5.7.14.5 Baxter’s Cartridges 86
5.7.15 Becton Dickinson and Company 87
5.7.15.1 BD’s Prefilled Syringe Services 87
5.7.15.2 BD Hypak SCF 87
5.7.15.3 BD Sterifill SCF 88
5.7.15.4 BD Physioject 88
5.7.15.5 BD Liquid Dry Disposable Pen Injector 89
5.7.15.6 BD Pens Customized Self-Injection Systems 89
5.7.15.7 BD Soluvia Prefillable Microinjection System 90
5.7.16 Catalent Pharma Solutions, Inc. 90
5.7.17 Hyaluron Contract Manufacturing 91
5.7.17.1 Hyaluron’s Syringe Filling 91
5.7.17.2 Vetter Pharma Fertigung GmbH 91
5.7.17.3 Vetter’s Development Service 92
5.7.17.4 Vetter’s Commercial Manufacturing 92
5.7.18 Global Market for Prefilled Syringes 92
5.7.18.1 Steady Growth in Consumption of Prefilled Syringe Units 93
5.7.19 U.S. Market for Prefilled Syringes 94
5.7.20 Rapid Adoption of Prefilled Syringes for Injectables 94
5.7.21 Pharmaceutical Consumption of Prefilled Syringes 95
5.7.22 Market for Pharmaceutical Prefilled Syringes 96
5.7.22.1 Global Market for Prefilled Pain Management Drugs 96
5.7.22.2 Global Sales of Enbrel in Prefilled Syringes 97
5.7.22.3 Global Market for Prefilled Psoriasis Drugs 98
5.7.22.4 Global Market for Prefilled Anemia Drugs 99
5.7.22.5 Global Market for Prefilled Disposable Insulin Delivery Devices 99
5.7.22.6 Global Market for Insulin in Various Devices 100
5.7.22.7 Global Market for Oncology Drugs in Prefilled Syringes 101
5.7.22.8 Global Market for Multiple Sclerosis Drugs in Prefilled Syringes 102
5.7.22.9 Market Leaders in Multiple Sclerosis Drugs in Prefilled Syringes 103
5.7.22.10 Global Market for Prefilled Arthritis Drugs 103
5.7.22.11 Global Market for Vaccines in Prefilled Syringes 104
5.7.22.12 Market Leaders in Injectable Vaccines 105
5.7.22.13 Market Leaders in Injectable Anticoagulants 106
5.7.23 Market Leaders in Injectable Anti-Inflammatory Drugs 107
5.7.24 Market Leaders in Injectable Hematology Drugs 108
5.7.25 Market Leaders in Injectable Obstetrics Drugs 109
5.8 Insulin Pens: Market Analysis 110
5.8.1 Disposable Insulin Pens 110
5.8.2 Refillable Pens 110
5.8.3 Pen Needles 110
5.8.4 Benefits and Patient Preferences of Insulin Pens 111
5.8.5 Disadvantages of Pen Syringes 111
5.8.6 Insulin Pens and Hospital Bills 112
5.8.7 Market for Insulin Pen 112
5.9 Global Market for Auto-Injectors/Auto-Infusers 113
5.9.1 U.S. Leaders in Insulin Pump Market 114
5.10 The Growth Market for Self-Injection 115

6. Company Profiles 116
6.1 Abbott Laboratories 116
6.1.1 Abbott’s Syringe Products 116
6.1.1.1 Precision Sure-Dose syringes 116
6.1.1.2 Humira Prefilled Syringe 117
6.1.1.3 Humira Pen 117
6.2 Albert David Limited 117
6.3 Alshifa Medical Syringes Manufacturing Company Ltd. 118
6.4 Althea Technologies, Inc. 119
6.5 Baxter International, Inc. 120
6.5.1 Baxter’s Anesthesia Business 120
6.5.2 Baxter’s Biosurgery 120
6.5.3 Baxter’s Clinical Nutrition Business 120
6.5.4 Baxter’s Hemophilia Therapies 121
6.5.5 Baxter’s Infusion Systems 121
6.5.6 Baxter’s Pharmaceuticals and IV Solutions 121
6.5.7 Baxter’s Renal Products 121
6.5.8 Baxter’s Business Performance 121
6.6 Becton, Dickinson & Co. 122
6.6.1 BD’s International Operations 122
6.6.2 BD Medical Business Segment 123
6.6.3 BD Diagnostics 124
6.6.4 BD Biosciences 124
6.6.5 BD’s Geographic Performance 125
6.6.6 BD’s Role in Designing Devices for Safe and Effective Injections and Infusions 126
6.6.6.1 BD’s Safety-Engineered Devices 126
6.6.6.2 BD Auto-Disable Syringes 128
6.6.6.3 BD’s Insulin Syringes 130
6.6.6.4 BD’s Allergy Syringes 131
6.6.6.5 BD’s Tuberculin Syringes 132
6.6.6.6 BD’s Syringes and Needles 133
6.6.6.7 BD’s Safety-Lok Safety Syringes 134
6.6.6.8 BD’s Safety Glide Syringes 135
6.6.6.9 BD’s Eclipse Needles 136
6.6.6.10 BD’s Integra Syringes 137
6.6.6.11 BD’s PosiFlush Prefilled Syringes 137
6.7 B. Braun 138
6.7.1 B. Braun’s Hospital Care Division 139
6.7.2 B. Braun’s Aesculap Division 139
6.7.3 B. Braun’s Out-Patient Market (OPM) Division 139
6.7.4 B. Braun’s Avitum Division 140
6.7.5 B. Braun’s Overall Business Performance 140
6.7.6 Hospital Care Division’s Business 140
6.7.7 Aesculap Division’s Business 140
6.7.8 OPM Division’s Business 141
6.7.9 Avitum Division’s Business 141
6.7.10 B. Braun’s Syringe Products 141
6.7.10.1 Sterican® insulin needle 141
6.7.10.2 Omnifix® 100 Duo 142
6.7.10.3 Omnifix 100 Solo 142
6.7.10.4 Injekt® 40 Duo 143
6.7.10.5 Injekt 40 Solo 143
6.7.10.6 Omnifix 40 Duo 144
6.7.10.7 Omnifix 40 Solo 144
6.7.10.8 Omnican® 100 145
6.7.10.9 Omnican® 50 145
6.7.10.10 Omnican® 20 146
6.7.10.11 Omnican 40 146
6.7.10.12 Omnican Pen 147
6.7.10.13 Omnican® fine 147
6.8 Bioject Medical Technologies, Inc. 147
6.8.1 Bioject’s Technology 147
6.8.2 Bioject’s Products 148
6.8.2.1 Biojector 2000 148
6.8.2.2  Bioject’s Drug Reconstitution System  
6.8.2.3  Vitajet  
6.8.2.4  ZetaJet  
6.9  Catalent Pharma Solutions, Inc.  
6.9.1  Catalent’s Development and Clinical Services Segment  
6.9.2  Catalent’s Oral Technologies Segment  
6.9.3  Catalent’s Sterile Technologies Segment  
6.9.4  Catalent’s Packaging Services Segment  
6.9.5  Catalent’s Syringe Solutions  
6.10  C.R. Bard, Inc.  
6.10.1  Bard’s Vascular Business  
6.10.2  Bard’s Urology Business  
6.10.3  Bard’s Oncology Business  
6.10.4  Bard’s Surgical Specialties Business  
6.10.5  Bard’s Syringe Products  
6.10.5.1  Bard’s Piston Syringes  
6.10.5.2  Bard’s Bulb Syringes  
6.11  Coeur, Inc.  
6.11.1  Angiographic Syringes from Coeur  
6.11.2  CT Syringes from Coeur  
6.12  Covidien Ltd.  
6.12.1  Covidien’s Medical Device Segment  
6.12.2  Covidien’s Pharmaceutical Segment  
6.12.3  Covidien’s Medical Supplies Segment  
6.12.4  Covidien’s Syringes and Needles  
6.12.4.1  Magellan Safety Needles  
6.12.4.2  Magellan Safety Needle and Syringe Combination  
6.12.4.3  Magellan Insulin Safety Syringe  
6.12.4.4  Magellan Tuberculin Safety Syringe  
6.12.4.5  Magellan Safety Blood Collection Device  
6.12.4.6  Monoject Insulin Safety Syringe  
6.12.4.7  Monoject Tuberculin Safety Syringe  
6.12.4.8  Monoject 3 ml Safety Syringe  
6.12.4.9  Monoject 6 ml Safety Syringe  
6.12.4.10  Monoject 12 ml Safety Syringe  
6.12.4.11  SoftPack Hypodermic Needles  
6.12.4.12  Rigid Pack Hypodermic Needles  
6.12.4.13  Rigid Blunt Cannulas  
6.12.4.14  Soft Pack Tuberculin Syringes  
6.12.4.15  Rigid Pack Tuberculin Syringes  
6.12.4.16  SoftPack Insulin Syringes  
6.12.4.17  Rigid Pack Insulin Syringes  
6.12.4.18  Allergy Trays with Permanently Attached Needles  
6.13  Henke-Sass, Wolf GmbH  
6.13.1  Selected Products from Henke-Sass  
6.13.1.1  Two-Part Disposable Syringes 1-50 ml  
6.13.1.2  Three-Part Disposable Syringes 1-30 ml  
6.13.1.3  Disposable Needles HSW FINE-JECT  
6.14  Hindustan Syringes & Medical Devices, Ltd.  
6.14.1  Insulin Syringes from HMD  
6.14.2  HMD’s Single-Use Needles  
6.14.3  HMD’s Single Use Syringes  
6.15  Hi-Tech Medical Products Ltd.  
6.16  Hyaluron Contract Manufacturing (HCM)  
6.16.1  HCM’s Major Markets  
6.16.2 HCM’s Facility 170
6.16.2.1 Inova SV-122 Syringe Filler 170
6.16.2.2 Inova H3-5V Syringe Filler 170
6.16.2.3 Inova VFVM-3031 Vial Filler 170
6.17 International Medication System Ltd. 171
6.17.1 Delivery Systems from IMS 171
6.17.2 PCA Products from IMS 173
6.17.3 Phytonadione Injection USP 173
6.17.4 Lidocaine HCL Jelly, USP 2% 174
6.18 Life-Shield Products, Inc. 174
6.19 MedPro Safety Products, Inc. 176
6.19.1 MedPro’s Targeted Markets 176
6.19.2 MedPro’s Products 176
6.19.2.1 Blood Collection Safety Needle 176
6.19.2.2 Winged Safety Blood Collection Set 177
6.19.2.3 Safety Syringe with Anti-Blunting Feature 177
6.19.2.4 Prefilled Safety Syringes 177
6.19.2.5 Key-Lok Needleless IV Systems 177
6.20 Merit Medical Systems, Inc. 178
6.20.1 Merit’s Inflation Devices 178
6.20.2 Merit’s Hemostasis Valves 178
6.20.3 Merit’s Vascular Access Products 178
6.20.4 Merit’s Diagnostic Catheters, Guide Wires and Torque Devices 179
6.20.5 Merit’s Angiography and Accessories 179
6.20.6 Merit’s Safety and Waste Management Systems 179
6.20.7 Merit’s Obesity Products 179
6.20.8 Merit’s Drainage Catheters and Accessories 179
6.20.9 Merit’s Parentesis and Pericardiocentesis Catheters 180
6.20.10 Merit’s Therapeutic Infusion Catheters 180
6.20.11 Merit’s Dialysis and Interventional Nephrology Products 180
6.20.12 Coronary Control Syringes 180
6.20.13 Medallion Syringes 181
6.20.14 RXP Syringe 181
6.20.15 VacLok Syringes 181
6.20.16 Merit’s Manufacturing Facilities 181
6.21 Milestone Scientific 182
6.21.1 Milestone Scientific’s Product Platform 182
6.21.1.1 STA Single Tooth Anesthesia System (STA System) 182
6.21.1.2 CompuDent 183
6.21.1.3 CompuMed 183
6.21.1.4 The Wand 183
6.21.1.5 The SafetyWand 184
6.22 Novo Nordisk A/S 184
6.22.1 Novo Nordisk’s Global Diabetes Care Business 184
6.22.1.1 Novo Nordisk’s Diabetes Care Business in North America 184
6.22.1.2 Novo Nordisk’s Diabetes Care Business in Europe 184
6.22.1.3 Novo Nordisk’s International Business in Diabetes Care 185
6.22.1.4 Novo Nordisk’s Diabetes Care Business in Japan and Korea 185
6.22.1.5 Insulin Pens and Needles from Novo Nordisk 185
6.22.2 Pipeline Progress in Novo Nordisk 185
6.22.3 Owen Mumford Ltd. 188
6.22.1 Autopen® 188
6.22.2 Autoject 2 189
6.22.3 Unifine Pentips 190
6.22.4 UniGuard 190
6.23 Plas-Pak Industries, Inc. 190
6.23.1 Disposable Veterinary Syringes 191
6.23.2 Dual Syringe and Dental Syringe from Plas-Pak 191
6.23.3 Manual Dual Syringes 192
6.24 Retractable Technologies, Inc. 193
6.24.1 Retractable Technologies' VanishPoint Products 193
6.25 RevVacs Safety Syringe 196
6.26 Safety Syringes, Inc. 196
6.26.1 UltraSafe Needle Guards 197
6.26.2 UltraSafe Passive Needle Guard 197
6.26.3 UltraSafe Passive Needle Guards for Luer Lock and Luer Slip Syringe 198
6.26.4 UltraSafe Automated Assembly 198
6.26.5 UltraSafe Product Development 198
6.27 Smiths Medical International/Medex, Inc. 199
6.27.1 Smiths Medical’s Markets 199
6.27.1.1 Smiths’ Medication Delivery Segment 200
6.27.1.2 Smiths’ Vital Care Segment 200
6.27.1.3 Smiths’ Safety Segment 200
6.27.2 Syringes from Smiths 201
6.27.2.1 Hypodermic Needle-Pro Fixed Needle TB Syringe 201
6.27.2.2 Hypodermic Needle-Pro Device 201
6.27.2.3 Hypodermic Needle-Pro Device & Syringe 203
6.27.2.4 Hypodermic Needle-Pro Device for Insulin Injections 204
6.27.2.5 Hypodermic Needle-Pro Fixed Needle Insulin Syringe 204
6.28 Star Syringe Ltd. 205
6.28.1 Star Syringe’s Alliances 205
6.28.2 Star Syringe Products 207
6.28.2.1 K Safety Technology: K1 Auto-disable Syringe Mechanism 207
6.28.2.2 K3 Safety Cap 207
6.28.2.3 K5 Aspiration 207
6.29 Terumo Medical Corporation 207
6.29.1 Terumo’s Syringe Products 208
6.29.1.1 SurGuard2 Syringes with Safety Needle 208
6.29.1.2 SurGuard2 Safety Needles 209
6.29.1.3 Terumo Hypodermic Needles 210
6.29.1.4 Terumo Hypodermic Syringes without Needle 211
6.29.1.5 Terumo Tuberculin Syringes 212
6.29.1.6 Terumo Hypodermic Syringes with Needle 213
6.29.1.7 SurSaver 1CC syringes with Low Dead Space 214
6.29.1.8 Terumo Dental Needles 214
6.29.1.9 Terumo Spinal Needles 215
6.29.1.10 SurGuard Safety Insulin Syringes 215
6.29.1.11 Terumo Insulin Syringes 216
6.29.1.12 Thinpro Insulin Syringes for Retail Customers 216
6.30 UltiMed, Inc. 217
6.30.1 UltiCare Insulin Syringes 217
6.30.2 UltiCare Pen Needles 218
6.31 Unilife Medical Solutions, Ltd. 219
6.31.1 Unilife’s Solutions 219
6.31.2 Prefilled Syringes from Unilife 219
6.31.3 Clinical (Hypodermic) Syringes from Unilife 219
6.31.4 Unilife’s Self Injection Systems 220
6.31.4.1 Auto-Injectors 220
6.31.4.2 Unilife’s Auto-Infusers 220
6.31.5 Unilife’s Syringe Products 221
6.31.5.1 Unifill Syringe 221
6.31.5.2 Unitract 1 ml Syringes 221
6.31.5.3 Unifill Select 222
6.31.5.4 Unifill Rita 222
6.31.5.5 Unifill EZMix syringes 222
6.31.5.6 Unilife Autoinfuser 222
6.32 Vetter Pharma-Fertigung GmbH & Co. 223
6.32.1 Vetter Services and Solutions 223
6.32.2 Vetter’s Dual-Chamber Technology 223
6.33 Vita Needle Company, Inc. 224
6.33.1 Disposable Stainless Steel Needle Blunts from Vita Needle 224
6.33.2 Teflon Dispensing Needles 224
6.33.3 Vita Needle’s Polypropylene Needles 225
6.33.4 Vita Needle’s Taper Tip Needles 225
6.34 West Pharmaceutical Services, Inc. 226
6.34.1 West’s Business Segments 226
6.34.1.1 Packaging Systems Segment 226
6.34.1.2 Delivery Systems Segment 226
6.34.2 West’s Syringe Products 227
6.34.2.1 The West ConfiDose Autoinjector System 227
6.34.2.2 West’s Prefillable Syringes 228
6.34.2.3 Plungers 229
6.34.2.4 Needle Shields 230
6.34.2.5 Tip Caps 230
6.35 Wuxi Yushou Medical Appliances Co., Ltd. 230
6.36 Ypsomed Holding AG 230
6.36.1 Future Trends in Self Medication: Ypsomed Holding’s Perceptions 231
6.36.2 ServoPen 233
6.36.3 YpsPen Twist 234
6.36.4 UnoPen 234
6.36.5 LyoTwist 235
6.36.6 YpsomeMate 235
6.36.7 Mylife OmniPod insulin patch pump 235

APPENDIX

Appendix 1: Global Market for Conventional Injectables 236
Appendix 1.1: Global Market for Drug Delivery Devices 237
Appendix 1.2: Evolving Trends in Insulin Delivery 238
Appendix 1.2.1: Alternative Modes of Insulin Delivery 238
Appendix 1.2.2: Insulin Injection Ports 239
Appendix 1.2.3: Continuous Subcutaneous Insulin Infusion Pumps 239
Appendix 1.2.4: Transdermal Patches 240
Appendix 1.2.5: Inhalable Insulin Devices 241
Appendix 1.3: Global Burden of Diabetes 241
Appendix 1.3.1: Market for Insulin Delivery Devices 242
Appendix 1.3.2: Leaders in Insulin Delivery Devices 242
Appendix 1.3.3: Global Insulin Consumption 243
Appendix 1.3.4: Global Market for Insulin 244
Appendix 1.4: Global Diabetes Care Market Share by Company 245
Appendix 1.4.1: Global Insulin Market by Molecule Type 245
Appendix 1.4.2: Global Insulin Market by Geography 246
INDEX OF FIGURES

Figure 2.1: Filling and Packaging of Prefilled Syringes
Figure 4.1: Most Common Instances When Needlesticks Occur
Figure 4.2: Needlestick Injuries in Massachusetts at Healthcare Facilities with Safety vs. Standard Syringes
Figure 4.3: Indicative Pricing Chart for Safety Features
Figure 5.1: Syringe Sizes Required for Injectable Drugs
Figure 5.2: Global Market for Disposable Syringes, 2012-2019
Figure 5.3: Global Market for Disposable Syringes by Segmentation, 2012
Figure 5.4: Combined Market for Drug Delivery Syringe Devices, 2010-2015
Figure 5.5: Breakdown of U.S. Syringe Market
Figure 5.6: Types of Safety Syringes used in the U.S. Healthcare Facilities
Figure 5.7: Percentage of U.S. Adoption of Safety Syringes, 2012-2019
Figure 5.8: The Total Disposable Syringe Market in the U.S., 2012-2019
Figure 5.9: Market Share of Prefilled Syringes by Geography
Figure 5.10: Number of Drugs in the Core Therapeutic Areas for Prefilled Syringes
Figure 5.11: Global Market for Disposable Syringes, 2012-2019
Figure 5.12: European Adoption of Safety Syringes, 2012-2019
Figure 5.13: European Overall Market for Disposable Syringes, 2011-2019
Figure 5.14: European Market for Drug Delivery Syringe Devices, 2010-2015
Figure 5.15: World vs. U.S. Market for Prefilled Syringes, 2012-2019
Figure 5.16: Steady Growth of Global Prefilled Syringe Unit Consumption, 2012-2019
Figure 5.17: Consumption of Prefilled Syringes by Pharmaceutical Company
Figure 5.18: Pharmaceutical Consumption of Prefilled Syringes by Therapeutic Drug Class
Figure 5.19: Global Market for Prefilled Pain Management Drugs, 2012-2019
Figure 5.20: Global Sales of Enbrel in Prefilled Syringes
Figure 5.21: Global Market for Prefilled Psoriasis Drugs, 2012-2019
Figure 5.22: Global Market for Prefilled Anemia Drugs, 2012-2019
Figure 5.23: Global Market for Prefilled Insulin, 2012-2019
Figure 5.25: Growth of Prefilled Insulin Devices and Decline of Vials and Syringes 101
Figure 5.26: Global Market for Oncology Drugs in Prefilled Syringes, 2012-2019 102
Figure 5.27: Global Market for Multiple Sclerosis Drugs in Prefilled Syringes, 2012-2019 103
Figure 5.28: Market Share for Multiple Sclerosis Drugs in Prefilled Syringes by Company 103
Figure 5.29: Global Market for Arthritis Drugs in Prefilled Syringes, 2012-2019 104
Figure 5.30: Percent Growth of Vaccines in Prefilled Syringes, 2012-2019 105
Figure 5.31: Market Share for Vaccines in Prefilled Syringes by Company 106
Figure 5.32: Market Share for Anti-Coagulants in Prefilled Syringes by Company 106
Figure 5.33: Market Share for Anti-Inflammatory Drugs in Prefilled Syringes 107
Figure 5.34: Market Share for Hematology Drugs in Prefilled Syringes by Company 108
Figure 5.35: Market Share for Obstetrics Drugs in Prefilled Syringes by Company 108
Figure 5.36: Global Market for Insulin Pen, 2012-2019 112
Figure 5.37: Global Market for Auto-Injectors/Auto-Infusers, 2012-2019 113
Figure 5.38: U.S. Leaders in Insulin Pumps 113
Figure 5.39: Market for Self-Injection Syringes, 2012-2019 114
Figure 6.1: BD Business Performance by Segment, 2012 122
Figure 6.2: Performance of BD Medical Segment, 2012 122
Figure 6.3: Performance of BD Diagnostics Segment, 2012 123
Figure 6.4: BD’s Geographic Performance, 2012 124
Figure 6.5: Share of Bioject’s Business by Customer 147
Figure 6.6: Bioject’s Business by Product Line 148
Figure 6.7: Bioject’s Business by Geography149
Figure 6.8: Catalent’s Revenue by Segment 152
Figure 6.9: Retractable Technologies’ Business by Geography 194
Figure 6.10: Smiths’ Market by Segment 199
Figure 6.11: Insulin Market by Geography, 2009-2015 231
Figure 6.12: Global Insulin Market by Manufacturers, 2009-2015 232
Figure A.1.1: Global Market for Conventional Injectables, 2012-2019 237
Figure A.1.2: Global Market for Injection, Infusion and Vascular Access Devices, 2012-2019 237
Figure A.1.3: Global Burden of Diabetes, 2010-2030 245
Figure A.1.4: Global Market for Insulin Delivery Devices, 2009-2016 242
Figure A.1.5: Insulin Delivery Devices Worldwide Market Shares by Company 243
Figure A.1.6: Insulin Consumption in Selected Countries 244
Figure A.1.7: Global Market for Insulin, 2012-2019 244
Figure A.1.8: Global Diabetes Care Market Share by Company, 2012 245
Figure A.1.9: Global Insulin Market Breakup by Molecule (~ $19 Billion), 2012 246
Figure A.1.10: Global Insulin Market by Geography, 2012 246
Figure A.1.11: Global Diabetes Care Market by Treatment Class, 2002-2012 247
Figure A.1.12: Shares of Human Insulin and Modern Insulin in Global Insulin Market, 2007-2012 248
Figure A.1.13: Global Insulin Volume Market Shares by Company, 2007-2012 249
Figure A.1.14: U.S. Insulin Market by Segment, 2007-2012 250
Figure A.1.15: U.S. Modern Insulin Volume Market Share by Company, 2007-2012 251
Figure A.1.16: E.U. Insulin Market by Segment, 2007-2012 252
Figure A.1.17: E.U. Modern Insulin Volume Market Share by Company, 2007-2012 253
Figure A.1.18: Chinese Insulin Market by Segment, 2007-2012 254
Figure A.1.19: China Insulin Volume Market Share by Company, 2012 255
Figure A.1.20: Japan Insulin Market by Segment, 2007-2012 255
Figure A.1.21: Japan Modern Insulin Market Share by Company, 2007-2012 256
Figure A.4.1: Timing of Needlestick Injuries293

INDEX OF TABLES

Table 2.1: Components of a Prefilled Syringe 23
Table 2.2: Key Advantages of Prefilled Syringes 26
Table 2.3: Insulin Pens Available in the U.S. 33
Table 2.4: Types of Insulins Used in Cartridges 34
Table 2.5: Aspects of Insulin Pens to be considered 35
Table 2.6: User Characteristics of Insulin Pens 36
Table 5.1: Selected Injectable Therapeutics and Vaccines Available in the U.S. Market 70
Table 5.2: Key Advantages of Prefilled Syringes 73
Table 5.3: Pharmaceutical Share of Key Prefilled Therapeutic Market 73
Table 5.4: Key Prefilled Products 74
Table 5.5: Biotech Blockbusters Available in Vials and Prefilled Syringes 78
Table 6.1: Albert David’s Syringes with Needles 117
Table 6.2: Albert David’s Needles 117
Table 6.3: Syringes from Alshifa 118
Table 6.4: BD’s Auto-Disable Syringes 129
Table 6.5: Insulin Syringes from BD 130
Table 6.6: BD’s Allergy Syringes 131
Table 6.7: BD’s Tuberculin Syringes 131
Table 6.8: BD’s Sterile, Single-Use Syringes and Needles 132
Table 6.9: BD’s Safety-Lok Safety Syringes 134
Table 6.10: BD’s Safety Glide Syringes 135
Table 6.11: BD’s Eclipse Syringes 135
Table 6.12: BD’s Integra Syringe 136
Table 6.13: BD’s PosiFlush Prefilled Syringes 137
Table 6.14: Bard’s Piston Syringes 155
Table 6.15: Bard’s Bulb Syringes and Trays, 2009 155
Table 6.16: Angiographic Syringes from Coeur 156
Table 6.17: CT Syringes from Coeur 157
Table 6.18: HMD’s Dispovan Insulin Syringes 167
Table 6.19: HMD’s Single-Use Needles 167
Table 6.20: HMD’s Single Use Syringes 168
Table 6.21: Hi-Tech Single-Use Syringes 168
Table 6.22: Hi-Tech’s Single-Use Insulin Syringes 169
Table 6.23: HCM’s Contract Manufacturing Categories 170
Table 6.24: Syringes from IMS 171
Table 6.25: PCA Syringes from IMS 172
Table 6.26: Phytonadione Injection USP from IMS 172
Table 6.27: Lidoacaine Prefilled Syringes from IMS 173
Table 6.28: Life-Shield’s Syringe Products 174
Table 6.29: Estimated Market for MedPro’s Targeted Product Sectors 175
Table 6.30: Autopen Products from Owen Mumford 188
Table 6.31: Autoject Products from Owen Mumford 188
Table 6.32: Unifine Products from Owen Mumford 189
Table 6.33: Retractable Technologies’ VanishPoint Syringes 193
Table 6.34: Smiths’ Pro Fixed Needle TB Syringes 200
Table 6.35: Smiths’ Needle-Pro with Needle Protection Devices 201
Table 6.36: Smiths’ Needle-Pro Syringe and Needle with Needle Protection Device 202
Table 6.37: Smiths’ Needle-Pro Needle Protection Device for Insulin Injections 203
Table 6.38: Smiths’ Needle-Pro Fixed Needle Insulin Syringe 204
Table 6.39: SurGard2 Syringes with Safety Needle 208
Table 6.40: Terumo’s SurGard2 Safety Needles 209
Table 6.41: Terumo’s Hypodermic Needles 210
Table 6.42: Terumo’s Hypodermic Syringes without Needle 211
Table 6.43: Terumo’s Tuberculin Syringes 211
Table 6.44: Terumo’s Hypodermic Syringes with Needle 212
Table 6.45 Terumo’s SurSaver 1 cc Syringes with Low Dead Space 213
Table 6.46: Terumo’s Dental Needles 213
Table 6.47: Terumo’s Spinal Needles 214
Table 6.48: Terumo’s SurGard Safety Insulin Syringes 215
Table 6.49: Terumo’s Insulin Syringes 215
Table 6.50: Thinpro Insulin Syringes 216
Table 6.51: UltiMed’s UltiCare Insulin Syringes 217
Table 6.52: UltiCare Pen Needles 217
Table 6.53: Vita Needle’s Stainless Steel Needle Blunts 223
Table 6.54: Vita Needle’s Teflon Dispensing Needles 224
Table 6.55: Vita Needles Polypropylene Needles 224
Table 6.56: Vita Needle’s Taper Tip Needles 224
Table A. 1.1: Alternative Modes of Insulin Delivery 238
Table A. 1.2: Types of Insulin Used in Pump Therapy 239
Table A. 1.3: Insulin Pumps Assessed by AFB TECH Company in 2004 and 2008 240
1. Introduction

1.1 Statement of Report

The report examines the disposable syringe market. It provides detailed forecasts for the traditional and safety-engineered sharps markets. It describes the major drivers and restraints, technology trends and industry challenges for the disposable syringe market. It examines the markets for blood collection sets, hypodermic access syringes and needles, sharps-based insulin delivery devices, and other specialty syringes and needles. Additionally, the study considers the disposable syringe supplies utilized in clinics and by patients in their homes to diagnose and monitor diseases, as well as to administer medications. This analysis is intended to provide basic market data pertaining to the U.S. and worldwide market segments. Each market segment is analyzed to determine size, growth rates, sales projections and factors influencing growth in the U.S. and internationally. Unit and dollar volumes have been used to indicate market sizes.

1.2 About this Report

The study specifically focuses on market dynamics, current market drivers and emerging trends within the disposable syringe markets. Additionally, this review examines industry challenges and potential threats to syringe and needle supply manufacturers. The emphasis is on those companies actively developing and marketing products to hospitals, physicians and the public for medically related uses. The reader should consult other TriMark reports at www.trimarkpublications.com for a detailed discussion of the important individual market segments related to syringes, such as glucose testing, blood constituent analyses as used in hospital, point-of-care and doctor’s office settings and diabetic markets.

1.2.1 Scope of the Report

The market segments for disposable syringes are:

- Prefilled syringes.
- Safety syringes.
- Insulin injector pens.
- Needleless injectors.
- Vaccination injectors.
- Blood collection needles and syringes.
- Hypodermic needles and syringes.
- Insulin needles and syringes.
- Specialty needles and syringes.

This analysis provides an overview of individual disposable syringe market segments, some of which possess the elements that will lead to high and sustained growth rates for the near future. The report also presents a description of the ancillary supplies marketed by major companies in each market segment. The study presents qualitative and quantitative data as well as information on key market measures and benchmarks such as:

- Market size by segment.
- Company market share.
- Product market share.
- Technology market share.
- Industry structure.
- Economic factors.
- Syringe design criteria.
- Product pricing.
- Emerging markets.
- Market projections.
- Strategic alliances.
• Proprietary technology.
• Technology factors.
• Market factors.
• Regulatory factors.

Technology areas include:

• Auto-Disable/Single-Use Syringes: Syringes that deactivate after one use and are especially useful for vaccinations in developing countries.
• Blood Collection Syringes and Needles: Winged and standard phlebotomy access devices.
• Retractable Syringes: In retractable syringes, the needles retract into the syringe barrel after use, so the barrel acts as the sharps container.
• Needleless Injectors: Injection devices that deliver the pharmaceutical through the skin without the use of a needle.
• Autoinjector Pens: In autoinjector pens, syringe automatically triggers to insert the needle to deliver the pharmaceutical.

This report does not cover peripheral devices such as lancing devices for patients with diabetes. Moreover, it does not discuss non-syringe devices such as breast examination kits, temperature-measuring devices, fertility control devices, condoms, gels or creams. This review, furthermore, does not cover disposable plastic supplies for the healthcare market unless the products designed specifically for use and sale in one of the designated market segments covered in this report.

A number of companies that market syringe products are primarily distributors of these products, rather than the primary developer. These companies—necessary and important to the medical products industry—are covered here to a limited degree. Concentration is placed on the disposable medical supplies market segment in important worldwide markets such as the U.S., Japan and Europe. It focuses primarily on the hospital market segment and, separately, on a description of the devices and supplies marketed by major companies in this segment for home use. Additionally, the report focuses on the vaccine segment of the disposable syringe market and its growth in developing countries.

1.2.2 Objectives

The primary objectives of this study are to:

• Identify important market drivers through a comprehensive look at various sales segments for disposable syringes.
• Obtain a complete understanding of the structure of the disposable syringe business from its basic principles to its applications.
• Discover feasible market opportunities by identifying high-growth applications in different medical areas, with a focus on the biggest and expanding markets.
• Focus on global industry developments through an in-depth analysis of the major world markets for disposable syringe supplies, including forecasts for growth.
• Define the disposable syringe market including definitions, processes and trends.
• Assess the market drivers and bottlenecks, from the perspective of the medical and commercial communities.
• Discuss the potential benefits of disposable syringes for various sectors of the medical and commercial communities.
• Establish the current total market size and future growth of the disposable syringe market, and analyze the current size and growth of individual segments.
• Provide current and forecasted market shares by company.
• Discuss profit and business opportunities by individual market segment.
• Provide strategic recommendations for near-term business opportunities.
• Assess current commercial uses of disposable syringes.
• Assess the disposable syringe business model.
• Analyze and evaluate safety syringe products, and assess the market potential for existing and probable future products.
• Analyze product designs, technologies and marketing challenges of syringe manufacturers.
• Provide detailed descriptions of segments in safety syringe market, market demographics and business strategies.
• Chart product sales data, market share and forecasts.
• Profile safety syringe companies, noting their product development activities, business strategies, and corporate alliances and affiliations

This report answers the following questions:

• What are the near term business opportunities in disposable syringes?
• What are the current and forecasted sizes of the disposable syringe market?
• What are the business models currently used by companies in disposable syringe market?
• What are the technologies used in disposable syringe supplies?
• Who holds the proprietary rights to disposable syringe technology?
• What regulatory processes must disposable syringes undergo in the U.S., Japan and Europe?
• How will technology changes in disposable syringes affect treatment and payment paradigms?
• How will litigation concerns increase physician and hospital use of disposables?
• How will technology reduce adverse growth trends and decrease total patient care cost?

1.2.3 Methodology

The author of this report has a Ph.D. with over 40 years of consulting experience. He has written over 1,000 articles and has published four books. The editor holds a Ph.D. and is a retired college professor with vast experience in biochemistry, biotechnology and pharmacology. He also has six years of experience in writing market research reports. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Health and Human Services (HHS) and U.S. federal agencies such as the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates’ databases and from TriMark’s private data stores. The information in this study was obtained from sources that TriMark believes to be reliable, but TriMark does not guarantee the accuracy, adequacy or completeness of any information or omission or nor does TriMark guarantee the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that are published annually. TriMark extracts relevant data and analytics from TriMark’s research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the
Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

**TriMark Publications Report, Research and Data Acquisition Structure**

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
  - Market and product segment grouping, and evaluating their relative significance.
  - Key competitors’ evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
  - Supply chain research and analysis to identify any factors affecting the market.
  - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis or further regional or national primary and secondary research.
- Completing a confirmatory primary research assessment of the report’s findings with the assistance of expert panel partners from the industry being analyzed.

1.3 **Executive Summary**

The main product groups within the syringe and needle sector of this report include disposable and safety syringes, injection pens, needleless injectors, insulin pumps and specialty needles. The disposable syringe market is driven substantially by the need for the safe administration and delivery of thousands of injectables that offer quick relief for diseases than the oral medications. According to the International Association of Safe Injection Technology, about 35 billion syringes are manufactured and used globally every year. Most of the therapeutic injectables are administered within healthcare facilities such as acute care hospitals and long-term care centers. Other consumers of syringes include patients who self-administer prescription medication such as insulin, government agencies that sponsor harm reduction programs and non-government organizations that conduct vaccination programs.

According to our estimates, the global disposable syringe market was worth about $6.3 billion in 2012 with a potential to reach $14.2 billion in 2019. In the U.S., approximately seven billion syringes are used annually, earning more than $1.3 billion in revenue. Initially, the European market used to prefer the glass syringes to plastic syringes. However, in the recent past, plastic syringes have gained much ground. The European market is dominated by several large dominant players that are active on a global scale. These manufacturers invest large amounts of resources in product innovation and development. The overall European market for disposable syringes in 2012 was worth about $230.75 million and it is predicted to grow and reach $264 million in 2019.

The three major segments in the global syringe market are traditional disposable syringes, safety syringes and prefilled syringes. Traditional disposable syringes continue to rule the market because of their affordable price in the developing markets. According to Revolutions Medical, about seven billion safety syringes were sold globally in 2011. Unilife Corporation estimates the volume of prefilled syringes sold in the global market in this period to be about three billion units. If these figures are analyzed together, the traditional disposable syringes constitute the largest segment with 71% share; its growth has been on the decline in the developed markets with the regulatory compulsions and rapid adoption of safety syringes. The safety syringe market is particularly strong in the developed markets and enjoys a share of 20% in the global disposable syringe market. Due to its ease of use, prefilled syringes have gained a market share of 9% and the future holds great promises for the prefilled syringes.

According to Medigard, the market for safety syringes was worth about $1.96 billion in and syringes with sheaths, manually retractable syringes and auto-retractable syringes had a 34%, 33% and 33% share respectively in...
this market. In the U.S., the syringe market primarily includes four different user groups: hospitals, physician offices, long-term care facilities and retail consumers. Hospitals consume the largest volume, representing about two thirds of the market. The retail group is the second largest group representing about % of the units sold, and includes syringes sold directly to patients and caregivers for the delivery of injectables, such as insulin, epinephrine and other drugs. In the U.S. market for safety hypodermic syringes alone was valued at $ with a potential to reach $ in Europe is rather lagging behind the U.S. in the adoption of safety syringes mainly because of the lack of legislation. There is no mandatory requirement for the use of safety syringes in Europe except the fact that most countries of the region have only issued broad guidelines for the use of safety syringes and the final decision has been left to the discretion of the purchasing agencies.

A thorough analysis of the different segments of syringe industry indicates the fact that the future belongs to prefilled syringes. The prefilled syringe industry will witness continued growth with the development of new vaccines, blood-stimulant drugs and therapeutic proteins. As more and more drug classes and therapeutic categories adopt prefilled syringes, the overall prefilled syringe market is expected to grow by % per year. The U.S. prefilled syringe market is growing at twice the speed of the European market. The market has been showing a growth rate of % and % for the U.S. and Europe respectively. Currently, the U.S. and Europe are the two largest markets for prefilled syringes and both are almost equal with % and %, respectively, in the global prefilled market sales. Today, prefilled syringes are the preferred drug delivery devices for more than injectables that are supplied by about pharmaceutical companies. The overall market for these injectables has been valued at about $ . Globally, the market value for prefilled syringes in was worth about $ and it has the potential to reach $ in . In the overall prefilled syringe market, vaccines account for %, anti-coagulants for %, drugs for multiple sclerosis for %, HGH for %, drugs for obstetrics for %, anti-inflammatory drugs for % and anti-infectives for %.

Nearly one billion insulin cartridges are filled each year for the global insulin pen market and almost half the cartridges are used in disposable pens and the other half in reusable pens. The rate of adoption of insulin pens has been higher in Europe than in the U.S. as U.S. healthcare facilities generally stick to the use of insulin syringes and vials. The convenience of insulin pens suits the needs of today’s insulin users. The U.S. market is more robust for insulin pumps. The global insulin pen market was worth about $ in with a potential to grow and reach $ in .